149 related articles for article (PubMed ID: 22536061)
21. Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor.
Agulnik M; Giel JL
Am J Clin Oncol; 2014 Aug; 37(4):417-22. PubMed ID: 22772433
[TBL] [Abstract][Full Text] [Related]
22. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
23. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
Gold JS; Dematteo RP
Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
[TBL] [Abstract][Full Text] [Related]
24. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
25. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
27. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
[TBL] [Abstract][Full Text] [Related]
28. Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.
Wang Y; Zhang P; Han Y; Nelson RS; McLeod HL; Tao K; Yuan Y; Zhang M; Xiang H; Zhou H
Chemotherapy; 2019; 64(4):197-204. PubMed ID: 31955170
[TBL] [Abstract][Full Text] [Related]
29. Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients.
Xu J; Ling TL; Wang M; Zhao WY; Cao H
Int Surg; 2015 May; 100(5):860-9. PubMed ID: 26011207
[TBL] [Abstract][Full Text] [Related]
30. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Turley RS; Peng PD; Reddy SK; Barbas AS; Geller DA; Marsh JW; Tsung A; Pawlik TM; Clary BM
Cancer; 2012 Jul; 118(14):3571-8. PubMed ID: 22086856
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.
Tan AD; Willemsma K; MacNeill A; DeVries K; Srikanthan A; McGahan C; Hamilton T; Li H; Blanke CD; Simmons CE
Curr Oncol; 2020 Jun; 27(3):e276-e282. PubMed ID: 32669934
[TBL] [Abstract][Full Text] [Related]
32. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
33. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
[TBL] [Abstract][Full Text] [Related]
34. 'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.
Sevinc A; Camci C
Chemotherapy; 2009; 55(1):11-4. PubMed ID: 18974643
[TBL] [Abstract][Full Text] [Related]
35. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Zaydfudim V; Okuno SH; Que FG; Nagorney DM; Donohue JH
J Surg Res; 2012 Oct; 177(2):248-54. PubMed ID: 22831567
[TBL] [Abstract][Full Text] [Related]
36. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
37. Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients.
Bischof DA; Kim Y; Blazer DG; Behman R; Karanicolas PJ; Law CH; Quereshy FA; Maithel SK; Gamblin TC; Bauer TW; Pawlik TM
J Am Coll Surg; 2014 Sep; 219(3):439-49. PubMed ID: 25065359
[TBL] [Abstract][Full Text] [Related]
38. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Gounder MM; Maki RG
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
[TBL] [Abstract][Full Text] [Related]
39. Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study.
Fauske L; Hompland I; Lorem G; Bondevik H; Bruland ØS
Clin Sarcoma Res; 2019; 9():6. PubMed ID: 31061697
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
